Literature DB >> 26303421

Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.

Eunah Kim, William H Bisson, Christiane V Löhr, David E Williams, Emily Ho, Roderick H Dashwood, Praveen Rajendran1.   

Abstract

Acetylation is an important, reversible post-translational modification affecting histone and non-histone proteins with critical roles in gene transcription, DNA replication, DNA repair, and cell cycle progression. Key regulatory enzymes include histone deacetylase (HDACs) and histone acetyltransferases (HATs). Overexpressed HDACs have been identified in many human cancers, resulting in repressed chromatin states that interfere with vital tumor suppressor functions. Inhibition of HDAC activity has been pursued as a mechanism for re-activating repressed genes in cancers, with some HDAC inhibitors showing promise in the clinical setting. Dietary compounds and their metabolites also have been shown to modulate HDAC activity or expression. Out of this body of research, attention increasingly has shifted towards non-histone targets of HDACs and HATs, such as transcriptions factors, hormone receptors, DNA repair proteins, and cytoskeletal components. These aspects are covered in present review, along with the possible clinical significance. Where such data are available, examples are cited from the literature of studies with short chain fatty acids, polyphenols, isoflavones, indoles, organosulfur compounds, organoselenium compounds, sesquiterpene lactones, isoflavones, and various miscellaneous agents. By virtue of their effects on both histone and non-histone proteins, dietary chemopreventive agents modulate the cellular acetylome in ways that are only now becoming apparent. A better understanding of the molecular mechanisms will likely enhance the potential to more effectively combat diseases harboring altered epigenetic landscapes and dysregulated protein signaling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26303421      PMCID: PMC5087604          DOI: 10.2174/1568026615666150825125857

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  221 in total

1.  Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.

Authors:  Chi-qi Chen; Kang Yu; Qing-xian Yan; Chong-yun Xing; Yi Chen; Zhuang Yan; Yi-fen Shi; Ke-wen Zhao; Shen-meng Gao
Journal:  Carcinogenesis       Date:  2013-02-21       Impact factor: 4.944

2.  Control of Smad7 stability by competition between acetylation and ubiquitination.

Authors:  Eva Grönroos; Ulf Hellman; Carl-Henrik Heldin; Johan Ericsson
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

3.  Acetylation site specificities of lysine deacetylase inhibitors in human cells.

Authors:  Christian Schölz; Brian T Weinert; Sebastian A Wagner; Petra Beli; Yasuyuki Miyake; Jun Qi; Lars J Jensen; Werner Streicher; Anna R McCarthy; Nicholas J Westwood; Sonia Lain; Jürgen Cox; Patrick Matthias; Matthias Mann; James E Bradner; Chunaram Choudhary
Journal:  Nat Biotechnol       Date:  2015-03-09       Impact factor: 54.908

4.  Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.

Authors:  Dong Hoon Kim; Jongheon Shin; Ho Jeong Kwon
Journal:  Exp Mol Med       Date:  2007-02-28       Impact factor: 8.718

5.  Differential prooxidative effects of the green tea polyphenol, (-)-epigallocatechin-3-gallate, in normal and oral cancer cells are related to differences in sirtuin 3 signaling.

Authors:  Ling Tao; Jong-Yung Park; Joshua D Lambert
Journal:  Mol Nutr Food Res       Date:  2014-11-17       Impact factor: 5.914

6.  Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.

Authors:  Tadahiro Shimazu; Matthew D Hirschey; John Newman; Wenjuan He; Kotaro Shirakawa; Natacha Le Moan; Carrie A Grueter; Hyungwook Lim; Laura R Saunders; Robert D Stevens; Christopher B Newgard; Robert V Farese; Rafael de Cabo; Scott Ulrich; Katerina Akassoglou; Eric Verdin
Journal:  Science       Date:  2012-12-06       Impact factor: 47.728

7.  Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.

Authors:  Shashwati Basak; Deepa Pookot; Emily J Noonan; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 8.  Physical and functional HAT/HDAC interplay regulates protein acetylation balance.

Authors:  Alessia Peserico; Cristiano Simone
Journal:  J Biomed Biotechnol       Date:  2010-12-05

9.  Genistein affects histone modifications on Dickkopf-related protein 1 (DKK1) gene in SW480 human colon cancer cell line.

Authors:  Huan Wang; Qian Li; Hong Chen
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

10.  Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers.

Authors:  Ying Hu; Graeme H McIntosh; Richard K Le Leu; Laura S Nyskohus; Richard J Woodman; Graeme P Young
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more
  19 in total

1.  Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.

Authors:  Luis D Godoy; Julianna E Lucas; Abigail J Bender; Samantha S Romanick; Bradley S Ferguson
Journal:  Mol Nutr Food Res       Date:  2017-02-06       Impact factor: 5.914

2.  A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells.

Authors:  Gavin S Johnson; Jia Li; Laura M Beaver; W Mohaiza Dashwood; Deqiang Sun; Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Mol Nutr Food Res       Date:  2017-01-03       Impact factor: 5.914

3.  The role of NADPH oxidase 1 in alcohol-induced oxidative stress injury of intestinal epithelial cells.

Authors:  Liuying Chen; Huikuan Chu; Lilin Hu; Zhonglin Li; Ling Yang; Xiaohua Hou
Journal:  Cell Biol Toxicol       Date:  2022-05-31       Impact factor: 6.691

Review 4.  Epigenomes in Cardiovascular Disease.

Authors:  Manuel Rosa-Garrido; Douglas J Chapski; Thomas M Vondriska
Journal:  Circ Res       Date:  2018-05-25       Impact factor: 17.367

Review 5.  Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases.

Authors:  Jelle Folkerts; Ralph Stadhouders; Frank A Redegeld; See-Ying Tam; Rudi W Hendriks; Stephen J Galli; Marcus Maurer
Journal:  Front Immunol       Date:  2018-05-29       Impact factor: 7.561

Review 6.  Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.

Authors:  Anna Wawruszak; Joanna Kalafut; Estera Okon; Jakub Czapinski; Marta Halasa; Alicja Przybyszewska; Paulina Miziak; Karolina Okla; Adolfo Rivero-Muller; Andrzej Stepulak
Journal:  Cancers (Basel)       Date:  2019-01-27       Impact factor: 6.639

Review 7.  H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.

Authors:  Marta Hałasa; Anna Wawruszak; Alicja Przybyszewska; Anna Jaruga; Małgorzata Guz; Joanna Kałafut; Andrzej Stepulak; Marek Cybulski
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

Review 8.  Different Flavors of Astrocytes: Revising the Origins of Astrocyte Diversity and Epigenetic Signatures to Understand Heterogeneity after Injury.

Authors:  Alejandro Villarreal; Tanja Vogel
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

Review 9.  Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.

Authors:  Terra Arnason; Troy Harkness
Journal:  Cancers (Basel)       Date:  2015-10-16       Impact factor: 6.639

10.  Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.

Authors:  Caleb J Yelton; Swapan K Ray
Journal:  Neuroimmunol Neuroinflamm       Date:  2018-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.